Cantor Fitzgerald Forecasts Strong Price Appreciation for Palvella Therapeutics (NASDAQ:PVLA) Stock

Palvella Therapeutics (NASDAQ:PVLA) had its price target hoisted by stock analysts at Cantor Fitzgerald from $120.00 to $200.00 in a research note issued on Thursday, MarketBeat reports. The brokerage presently has an “overweight” rating on the stock. Cantor Fitzgerald’s price objective points to a potential upside of 156.97% from the company’s current price.

Several other analysts have also recently weighed in on the company. Truist Financial lifted their price target on Palvella Therapeutics from $56.00 to $80.00 and gave the stock a “buy” rating in a report on Thursday, October 2nd. Chardan Capital increased their price objective on Palvella Therapeutics from $60.00 to $73.00 and gave the stock a “buy” rating in a research report on Friday, September 26th. Lifesci Capital began coverage on Palvella Therapeutics in a report on Monday, August 4th. They set an “outperform” rating and a $90.00 target price for the company. Oppenheimer started coverage on shares of Palvella Therapeutics in a research note on Tuesday, September 9th. They issued an “outperform” rating and a $85.00 price target on the stock. Finally, Raymond James Financial set a $54.00 price target on shares of Palvella Therapeutics and gave the stock an “outperform” rating in a research report on Tuesday, August 5th. One investment analyst has rated the stock with a Strong Buy rating, eleven have given a Buy rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, Palvella Therapeutics presently has a consensus rating of “Moderate Buy” and an average price target of $97.58.

Palvella Therapeutics Stock Down 1.0%

Shares of Palvella Therapeutics stock opened at $77.83 on Thursday. The stock has a market cap of $860.80 million, a P/E ratio of -20.54 and a beta of -0.05. Palvella Therapeutics has a 12-month low of $11.17 and a 12-month high of $83.00. The business’s 50 day moving average is $66.13 and its 200-day moving average is $42.75.

Palvella Therapeutics (NASDAQ:PVLA) last posted its quarterly earnings results on Thursday, August 14th. The company reported ($0.86) EPS for the quarter, missing analysts’ consensus estimates of ($0.78) by ($0.08). On average, sell-side analysts expect that Palvella Therapeutics will post -3.69 EPS for the current year.

Institutional Trading of Palvella Therapeutics

A number of institutional investors and hedge funds have recently added to or reduced their stakes in PVLA. Royce & Associates LP bought a new stake in Palvella Therapeutics in the first quarter worth approximately $2,002,000. Frazier Life Sciences Management L.P. grew its stake in Palvella Therapeutics by 5.5% in the first quarter. Frazier Life Sciences Management L.P. now owns 690,012 shares of the company’s stock valued at $19,313,000 after acquiring an additional 36,120 shares during the period. AWM Investment Company Inc. bought a new stake in shares of Palvella Therapeutics during the first quarter valued at approximately $1,943,000. Millennium Management LLC acquired a new position in shares of Palvella Therapeutics during the first quarter worth approximately $7,553,000. Finally, Goldman Sachs Group Inc. bought a new position in shares of Palvella Therapeutics in the 1st quarter worth $533,000. Institutional investors and hedge funds own 40.11% of the company’s stock.

Palvella Therapeutics Company Profile

Palvella Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapies to treat patients suffering from serious, rare genetic skin diseases. Palvella Therapeutics Inc, formerly known as Pieris Pharmaceuticals Inc, is based in WAYNE, Pa.